Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
# | Type | Title | Authors | Category | Keywords |
---|---|---|---|---|---|
89 | Poster Presentation | First-in-human CAR T targets cleaved MUC1, the growth factor receptor form | Benoit J. Smagghe, PhD; Andrew K. Stewart, PhD; Pengyu Huang, PhD; Tyler E. Swanson; Danica M. Page; Mark G. Carter; Trevor J. Grant, PhD; Jennifer Specht, MD; Cynthia C. Bamdad, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Stem cell/cancer-initiating cell; T cell; Targeted therapy |
90 | Oral Presentation | Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway | Jonathan Boiarsky, BA; Ranjan Upadhyay, PhD; Judit Svensson-Arvelund, PhD; Aleksandra Wroblewska, PhD; Sherry Bhalla, PhD; Nathalie Scholler, MD, PhD; Adrian Bot, MD, PhD; John M. Rossi, MS; Samir Parekh, MD; Norah Sadek, BA; Alessia Baccarini, PhD; Miriam Merad, MD, PhD; Brian Brown, PhD; Joshua Brody, MD; | Cellular Therapies | Bispecifics; CAR T cells; Immune tolerance; Leukemia/Lymphoma; T cell; Tumor antigens; Tumor evasion |
91 | Poster Presentation | Directly Link T Cell Phenotype and Function to Genotype with the Opto™ Cell Therapy Development 1.0 Workflow | Yelena Bronevetsky, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; T cell |
92 | Poster Presentation | Adoptive transfer of immature myeloid cells lacking NF-κB p50 (p50-IMC) slows high-risk neuroblastoma tumor growth | Cheng Cui, Ph.D.; Theresa Barberi, PhD; Rahul Suresh, Ph.D.; Ludovic Zimmerlin, Ph.D.; Elias Zambidis, M.D., Ph.D.; Alan D. Friedman, MD; | Cellular Therapies | Adoptive immunotherapy; Monocyte/Macrophage; Myeloid cells; Pediatric tumors |
93 | Poster Presentation | Targeting Sirt2 rescues the metabolic fitness and effector functions of tumor-reactive T cells within the metabolically restricted tumor microenvironment | Imene Hamaidi, PhD; Lin Zhang, MD. Ph.D; Nayoung Kim, PhD; Min-Hsuan Wang; Cristina Iclozan, Ph.D.; Bin Fang, PhD; Min Liu, Ph.D.; John M. Koomen, PhD; Anders E. Berglund, PhD; Sean J. Yoder; Jiqiang Yao, PhD; Robert W. Engelman, PhD; Ben C. Creelan, MD, MS; Jose R. Conejo-Garcia, MD, PhD; Scott J. Antonia, MD PhD; James J. Mule, PhD; Sungjune Kim, MD PhD; | Cellular Therapies | Checkpoint blockade; Metabolism; Post-translational modifications; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
94 | Poster Presentation | The T cell Antigen Coupler (TAC) redirects T cell oncolysis while limiting tonic signaling to create a safer engineered T cell product with a higher threshold for activation | Duane Moogk, PhD; Vivian W. Lau; Arya Afsahi, MSc; Anna Dvorkin-Gheva, PhD; Ksenia Bezverbnaya; Joanne A. Hammill, PhD; Jonathan L. Bramson, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Immune toxicity |
95 | Poster Presentation | Inhibition of AKT signaling during expansion of TCR-engineered T-cells from patient leukocyte material generates SPEAR T-cells with enhanced functional potential in vitro | Katerina Mardilovich; Lilli Wang; Rachel Kenneil; Gareth Betts, PhD; Natalie Bath, MSc; Will Spinner; Vanessa De Mello; Seint Lwin; Joseph P. Sanderson, PhD; Jonathan D. Silk, PhD; Alex J. Tipping, PhD; Andrew B. Gerry, PhD; Phil Bassett; Karen Miller, PhD; Mark Dudley; Emily Schmidt | Cellular Therapies | Adoptive immunotherapy; T cell; Targeted therapy |
96 | Poster Presentation | Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo | Dmitry Pankov; Ioanna S. Eleftheriadou; Anna Domogala; Sara J. Brett, PhD; Lea Patasic; Magdalena A. Kijewska; Gary Thripp; Jack Euesden; Jan Klapwijk; Katrina Soor; Miriam Damm; Mark D. W. Hill; Mirella Georgouli; Aiman Shalabi; Cedrik Britten; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Epigenetics; Gene expression; Solid tumors; T cell; Tumor antigens |
97 | Poster Presentation | Polyfunctional activity of GD3CAR T-cells against tumors in Tuberous Sclerosis Complex | Ancy Thomas, PhD; Emilia Dellacecca; Rohan Shivde; Nicola Lanki; Levi Barse; Ancy Thomas, PhD; Agnes Lo; Denise M. M. Scholtens; Daniel F. Dilling; Richard P. Junghans, PhD, MD; Caroline Le Poole; | Cellular Therapies | CAR T cells; Cytokine; Solid tumors; T cell; Targeted therapy |
98 | Poster Presentation | ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors | Jiangyue Liu, MS; Xianhui Chen, PhD; Jason Karlen; Alfonso Brito, MS; Tiffany Jheng, MS; Philippe Foubert, PhD; Janani Krishnamurthy, PhD; Yannick Bulliard, PhD; Blake T. Aftab, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Immune suppression; Targeted therapy; Tumor antigens; Tumor microenvironment |
99 | Poster Presentation | Structural optimization of anti-CEA-GITR-CAR to reduce tonic signaling and improve antigen-specific reactivity | Yasunori Amaishi; Yu Okubo, PhD; Yizheng Wang; Linan Wang, PhD; Takuma Kato, PhD; Sachiko Okamoto, PhD; Hiroshi Shiku, PhD; Junichi Mineno, PhD; | Cellular Therapies | CAR T cells; Solid tumors; T cell; Tumor antigens |
100 | Poster Presentation | Drug-regulatable engineered T cells eliminate CD33+ and CD33ΔE2+ AML | Jacob S. Appelbaum, MD, PhD; Wai-Hang Leung; Unja Martin; Kaori Oda; Giacomo Tampella, PhD; Dong Xia; Joy Zhang; Anne-Rachael Krostag; Rachael Logan; Claudya Evandy; Quennie Vong; Kyle S. Jones; John C. Timmer, PhD; Brendan P. Eckelman, PhD; Jim Rottman; Danielle Montt; Bryan Peguero; Mark Pogson; Alexander Astrakhan; Jordan Jarjour, PhD; Joshua Gustafson, PhD; Michael C. Jensen, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Myeloid cells |
101 | Poster Presentation | Engineering gamma/delta T cells with the T-Cell Antigen Coupler receptor effectively induces antigen-specific tumor cytotoxicity in vitro and in vivo | Sarah E. Asbury, BSc; Seung Mi Yoo, PhD; Jonathan L. Bramson, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell |
102 | Poster Presentation | Cord-blood derived NK cells, and CAR-T cells, an attractive improved immunotherapy treatment to be considered for hematological malignancies | Mireia Bachiller García, Pharm; Lorena Pérez-Amill; Anthony M. Battram, PhD; Alvaro Urbano-Ispizua; Beatriz Martín-Antonio; Mireia Bachiller García, Pharm; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Myeloid cells; NK/NK T cell; Targeted therapy |
103 | Poster Presentation | Inclusion of a Dap10 costimulatory domain enhances anti-tumor efficacy of chimeric PD1-expressing T cells in multiple types of solid tumors | Amorette Barber, Ph.D.; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Solid tumors |
104 | Poster Presentation | BCMA-targeting CAR-T cells expanded in IL-15 have an improved phenotype for therapeutic use compared to those grown in IL-2 or IL-15/IL-7 | Anthony M. Battram, PhD; Mireia Bachiller, Pharm; Álvaro Urbano-Ispizua; Beatriz Martin-Antonio, Jr.; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; T cell |
105 | Poster Presentation | A third-generation human GUCY2C-targeted CAR-T cell for colorectal cancer immunotherapy | Trevor R. Baybutt, BA; Adam E. Snook, PhD; Scott A. Waldman, MD, PhD; Jonathan M. Stem, MD; Ellen Caparosa, MD; Alicja Zalewski, MD; Trevor R. Baybutt, BA; | Cellular Therapies | CAR T cells; Solid tumors; T cell |
106 | Poster Presentation | Increasing AMPK activity in human T cells enhances memory subset formation without sacrificing in vitro expansion | Erica Braverman, MD; Andrea Dobbs, MSc; Darlene A. Monlish, PhD; Craig Byersdorfer, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Metabolism; T cell lineages |
107 | Poster Presentation | Effects of IL-2 and IL-15 on the proliferative and antitumor capacities of allogeneic CD20 CAR-engineered γδ T cells in a 3D B cell lymphoma spheroid assay | Lu Bai; Kevin Nishimoto; Mustafa Turkoz; Marissa Herrman; Jason Romero; Daulet Satpayev; Stewart Abbot; Sandra M. Hayes; Mary M. Brodey, Ph.D.; | Cellular Therapies | CAR T cells; Cytokine; Leukemia/Lymphoma; Tumor microenvironment |
108 | Poster Presentation | MCY-M11, a CAR-PBMC cell product transiently expressing a mesothelin targeted mRNA CAR, exhibits desirable functional and immune phenotype attributed to sustained antitumor immunity in vitro | Sashi Kasimsetty, PhD; Himavanth Gatla, PhD; Dhana Chinnasamy, PhD; | Cellular Therapies | Antigen presenting cells; B cell; CAR T cells; Clinical study; Costimulation; Dendritic cell; Monocyte/Macrophage; NK/NK T cell; RNA; T cell |
109 | Poster Presentation | Dominant-negative TGFβ receptor 2 enhances GPC3-targeting CAR-T cell efficacy against hepatocellular carcinoma | Nina J. Chu, PhD; Michael Overstreet, PhD; Ryan Gilbreth; Lori Clarke; Christina Gesse; Eric Tu; Letizia Giardino; Gordon Moody; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
110 | Poster Presentation | In-depth characterization of variability in apheresis collections from normal donor populations for allogeneic cell therapy | Shawn P. Fahl, PhD; | Cellular Therapies | B cell; Biomarkers; CAR T cells; Genetic polymorphism; Immune monitoring; NK/NK T cell; T cell; T cell lineages; Targeted therapy |
111 | Poster Presentation | Highly efficient multiplexed base editing enables development of universal CD7-targeting CAR-T Cells to treat T-ALL | Jason Gehrke, PhD; Aaron Edwards; Ryan Murray; Angelica Messana; Lindsey Coholan; Henry Poulin; Melissa Le; Alden Ladd; Mark Naniong; Faith Musenge; Adam Camblin; Yeh-Chuin Poh; Sarah Smith; Giuseppe Ciaramella; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; T cell |
112 | Poster Presentation | Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy | Letizia Giardino; Ryan Gilbreth; Cui Chen; Erin Sult; Noel Monks; Ravinder Tammali; Jon Chesebrough; Kevin Schifferli; Nina Chu; Jessica Tong; Lori Clarke,; Christina Gesse; Xiao-Tao Yao; Karma DaCosta; Kapil Vashisht; Gordon Moody; Letizia Giardino; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy |
113 | Poster Presentation | Development of T cell-based immunotherapies to target dormant disseminated breast cancer cells | Erica T. Goddard, PhD; Shivani Srivastava, PhD; Stanley R. Riddell, MD; Cyrus Ghajar, PhD; Erica T. Goddard, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Tumor microenvironment |
114 | Poster Presentation | Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing | John Goulding, PhD; John Goulding, PhD; Mochtar Pribadi, PhD; Robert Blum, MS; Wen-I Yeh, PhD; Yijia Pan, PhD; Svetlana Gaidarova, MS; Chia-Wei Chang, PhD; Hui-Yi Chu, PhD; Ellen Liu, MS; Shohreh Sikaroodi, PhD; Lucas Ferrari de Andrade, PhD; Lauren Fong, PhD; Janel Huffman, MS; Tom T. Lee, PhD; Ryan Bjordahl, PhD; Kai W. Wucherpfennig, MD, PhD; Bahram Valamehr, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor evasion |
115 | Poster Presentation | Engineered T cells directed at tumors with defined allelic loss | Agi Hamburger, PhD; Breanna DiAndreth; Jiajia Cui; Mark Daris, PhD; Melanie Munguia; Kiran Deshmukh; Jee-Young Mock; Grace Asuelime; Emily Lim; Michelle Kreke; Talar Tokatlian; Alexander Kamb, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell |
116 | Poster Presentation | Multi-antigen targeting of heterogenous solid tumors using CAR T cells secreting bi-specific T-cell engagers | Martin Hosking, PhD; Bishwas Shrestha; Megan M. Boyett; Soheila Shirinbak; Angela Gentile; Eric Sung; Yijia Pan, PhD; Tom T. Lee, PhD; Jason ORourke; Dan Shoemaker, PhD; Cokey Nguyen; Bahram Valamehr, PhD; | Cellular Therapies | Adoptive immunotherapy; Bispecifics; CAR T cells; Solid tumors; Tumor evasion |
117 | Poster Presentation | Rapid point-of-care subcutaneous CAR-T from blood draw to injection in 4 hours with modified LV encoding CARs and synthetic driver elements enables efficient CAR-T expansion and tumor regression | Frederic Vigant, PhD; Qun He, PhD; Wei Zhang, PhD; Hongliang Zong, MD, PhD; Anirban Kundu; Ewa Jaruga-Killeen, PhD; Gregory Schreiber, PhD; Michelle Andraza; Alissa Kerner, PhD; Gregory I. Frost, PhD | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; T cell; Targeted therapy |
119 | Poster Presentation | IL-6 is critical for memory responses elicited by Th17 cells to tumors | Hannah M. Knochelmann, BS; Connor J. Dwyer, PhD; Aubrey S. Smith, BS; Megan Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Gregory B. Lesinski, PhD; Zihai Li, MD, PhD; Mark P. Rubinstein, PhD; Chrystal M. Paulos, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; Immune toxicity; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
120 | Poster Presentation | P-MUC1C-ALLO1: An Allogeneic CAR-T for Multiple Solid Tumor Indications | Anna K. Kozlowska, PhD; Yan Zhang, PhD; Jacqueline Fritz, BS; Steven Wang, PhD; Rebecca A. Codde, BS; Elvira Argus, PhD; Samad A. Ibitokou, PhD; Vanitra Richardson, MS; Sumiti Jain, PhD; Maximilian Richter, PhD; Deepak Patil, PhD; Yening Tan, MS; Min Tong, MS; Lu Yao, PhD; Majid Ghoddusi, PhD; Eric M. Ostertag, MD, PhD; Julia Coronella, PhD; Devon J. Shedlock, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell |
122 | Oral Presentation | Guanylyl cyclase C as a target for CAR-T cell therapy in a metastatic gastric cancer model | Amanda N. Lisby, MS; Trevor R. Baybutt, BA; Megan Weindorfer, BS; Robert Carlson, BS; Alicja Zalewski, MD; Scott A. Waldman, MD, PhD; Adam E. Snook, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Biomarkers; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor antigens |
123 | Poster Presentation | Natural killer cells engineered with an inducible, responsive genetic construct targeting TIGIT and CD73 to relieve immunosuppression within the GBM microenvironment | Kyle B. Lupo, BS; Sandro Matosevic, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NKT cell; Solid tumors; Targeted therapy; Tumor microenvironment |
124 | Poster Presentation | Optimizing the Generation from Umbilical Cord Blood of “Off-the-Shelf” CD19-Chimeric Antigen Receptor (CAR) expressing T cells | Cristina Maccalli, PhD; Asma Al Sulaiti, Bachelor; Moza Al Khulaifi; Shilpa Ravindran, MSc; Mohammed El-Anbari; Mohammed Toufiq; Rebecca Mathew; Chiara Bonini; Monica Casucci, PhD; Chiara Cugno, MD; Suruchi Mohan; Sara Deola; Damien Chaussabel; Sara Tomei, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; Gene expression; Leukemia/Lymphoma; T cell; T cell lineages |
125 | Poster Presentation | Reexamination of MAGE-A3 as a T-cell Therapeutic Target | Aaron D. Martin, M.A.; Xueyin Wang, PhD; Han Xu, PhD; Alexander S. Kamb; Mark Sandberg, PhD; Kathleen Negri; Ming Wu; Dora Toledo Warshaviak, PhD; Grant Gabrelow; Michele Mcelvain; Mark Daris, PhD; Bella Lee; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell; Targeted therapy |
126 | Poster Presentation | Early-phenotype Lewis Y CAR-T cells persist better in vivo and induce solid tumor regression in combination with anti-PD1. | Deborah Meyran, MD; Joe Zhu; Jeanne Butler; Sean Macdonald; Daniela Tantalo; Niko Thio; Kevin Sek; Paul Ekert; Michael H. Kershaw, PhD; Joe Trapani; Phillip K. Darcy; Paul J. Neeson, PhD; | Cellular Therapies | CAR T cells; Checkpoint blockade |
127 | Poster Presentation | Preclinical evaluation of NKX019, a CD19-targeting CAR NK Cell | Nadege Morisot; Sarah Wadsworth; Tina Davis; Nicole Dailey; Kyle Hansen; Denise Gonzalez; Nafees Rahman; Alex Aronov; Y Fan; Chao Guo; Luxuan Buren; Anmol Vohra, MS; Kate Jamboretz; H Leman; Sasha Lazetic, BA; Ivan Chan, PhD; James T. Trager, PhD; Joanne BT. Tan; | Cellular Therapies | Adoptive immunotherapy; Leukemia/Lymphoma; NK/NK T cell |
128 | Poster Presentation | Development of an M1-polarized, non-viral chimeric antigen receptor macrophage (CAR-M) platform for cancer immunotherapy | Yumi Ohtani, PhD; Kayleigh Ross; Aditya Dandekar; Rashid Gabbasov, PhD; Michael Klichinsky, PharmD, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Gene expression; Monocyte/Macrophage; Myeloid cells; Solid tumors; TLR; Tumor microenvironment |
129 | Poster Presentation | A novel CAR conducting antigen-specific JAK-STAT signals demonstrates superior antitumor effects with minimal undesired non-specific activation | Sachiko Okamoto, PhD; Sachiko Okamoto, PhD; Yasunori Amaishi; Mitsuki Shigeta, PhD; Yu Okubo, PhD; Yota Ohashi; Naoto Hirano, MD, PhD; Junichi Mineno, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Costimulation; Leukemia/Lymphoma; Solid tumors; T cell; Tumor antigens |
130 | Poster Presentation | Immunogenic potential of chimeric antigen receptor (CAR)-engineered T cells expressing inducible nuclease-deactivated SpCas9 (dCas9) | Dharmeshkumar Patel, PhD, MS; Angshumala Goswami; Vitaly Balan; Zhifen Yang, Dr.; Lingyu Li, PhD; Sowndharya Rajavel, Sr.; Alper Kearney, PhD; Rona Harari-Steinfeld; Maggie Bobbin; Bing C. Wang, PhD; Alessandra Cesano, MD, PhD; Stanley L. Qi, Ph.D.; Francesco M. Marincola, MD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Immune monitoring; Immune toxicity; Solid tumors; T cell; Targeted therapy |
131 | Poster Presentation | CoupledCAR® Technology Strengthens Adoptive T Cell Therapy by Promoting Rapid Expansion | Zhiyuan Cao; Chengfei Pu; Xianyang Jiang; Xiaogang Shen; Ruihong Zhu; Yuzhe Peng; Xi Huang; Zhao Wu; Lei Xiao, Ph.D.; | Cellular Therapies | Adoptive immunotherapy; Biomarkers; CAR T cells; Clinical study; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens |
132 | Poster Presentation | CAR macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD1 blockade in immunocompetent mouse models of HER2+ solid tumors | Stefano Pierini, PhD; Rashid Gabbasov, PhD; Linara Gabitova, PhD; Yumi Ohtani, PhD; Michael Klichinsky, PharmD, PhD; | Cellular Therapies | Monocyte/Macrophage; Myeloid cells; Solid tumors |
133 | Poster Presentation | Development of novel cellular therapeutics for metastatic and primary CNS malignancies | Paul D. Rennert, PhD; Alyssa Birt; Lihe Su, PhD; Lan Wu, PhD; Fay J. Dufort, PhD; Roy R. Lobb, PhD; Christine Ambrose, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Bispecifics; CAR T cells; Pediatric tumors; Solid tumors; Tumor antigens |
134 | Poster Presentation | Tumor-responsive, multi-functional genetically-engineered natural killer cells for immunotherapy of glioblastoma | Jiao Wang, PhD; Yeonhee I. Yun; Karen E Pollok; Anthony L. Sinn; Randy R Brutkiewicz; Michael C Veronesi; Sandro Matosevic, PhD; Jiao Wang, PhD; | Cellular Therapies | Adoptive immunotherapy; Chemokine; Immune suppression; Metabolism; NK/NKT cell; Solid tumors; Tumor antigens; Tumor evasion; Tumor microenvironment; Tumor stroma |
136 | Poster Presentation | Targeting MET with Chimeric Antigen Receptor T cells in Hepatocellular Carcinoma | Yuan Qin; Anna Qin; Anna Musket; Joseph Lee; Zhi Q. Yao; Giedre Krenciute, PhD; Qian Xie; Qian Xie | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Targeted therapy |
137 | Poster Presentation | Genomics of multiple myeloma influences the expression of CAR T-cell targets | Christina Y. Yu, BSc; Brian A. Walker, PhD; G. David Roodman, MD, PhD; Kun Huang, PhD; Michel Sadelain, MD PhD; Fabiana Perna, MD, PhD; | Cellular Therapies | B cell; Bioinformatics; CAR T cells; Gene expression; Targeted therapy |
138 | Poster Presentation | In vivo localization of genetically engineered natural killer cells against glioblastoma using PET imaging | Yeonhee I. Yun; Jiao Wang, PhD; Karen Pollok; Tony Sinn; Randy Brutkiewicz; Sandro Matosevic, PhD; Michael Veronesi; | Cellular Therapies | Chemokine; Immune suppression; Metabolism; NK/NKT cell; Radiotherapy; Solid tumors; Tumor antigens; Tumor evasion |
139 | Poster Presentation | Establishment of canine CAR T cells treatment model for solid tumor immunotherapy development | Shihong Zhang, Ph.D; Karan Kohli, Ph.D; R. Graeme Black; Brian J. Hayes, Ph.D; Cassandra Miller, DVM; Mari Maeda-Whitaker, PhD; Brett A. Schroeder, MD; Kraig Abrams; Bernard Seguin, DVM; Stephen Gottschalk, MD; Peter F. Moore, DVM, Ph.D.; Beverly J. Torok-Storb, Ph.D; Seth M. Pollack, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Tumor antigens |
140 | Poster Presentation | Adoptive transfer of T cells surface-tethered with IL-12 promote antigen spreading for enhanced anti-tumor efficacy | Ditte E. Jaehger, PhD; Kate L. Stokes, PhD; Hólmfridur R. Halldórsdóttir, MSc; Alvin Pratama, PhD; Gulzar Ahmad, PhD; Jonathan D. Nardozzi, PhD.; Katharine Sackton, PhD; Douglas Jones, PhD; Thomas L. Andresen, PhD; | Cellular Therapies | Adoptive immunotherapy; Dendritic cell; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
141 | Poster Presentation | PBMC-based cancer vaccines generated with microfluidics squeezing demonstrate synergistic and durable tumor reduction in combination with PD1 checkpoint and FAP targeted IL-2 variants | Matthew G. Booty, PhD; Adam Stockmann; Olivia Pryor; Melissa Myint, PhD; Christine Trumpfheller, PhD; Valeria G. Nicolini; Christian Klein, Dr rer nat; Laura Codarri, Dr.; Pablo Umana, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Katherine Seidl, PhD; Scott M. Loughhead, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Bispecifics; Checkpoint blockade; Cytokine; Tumor microenvironment; Vaccine |
142 | Poster Presentation | Contextual reprogramming of CAR T cells for the treatment of HER2-expressing cancers | Zhifen Yang, Dr.; Lingyu Li, PhD; Ahu Turkoz, Ph.D.; Pohan Chen, MS; Hana Choi, MS; Damla Inel, MS; Stanley L. Qi, Ph.D.; Francesco M. Marincola, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Costimulation; Immune contexture; Solid tumors; T cell lineages; Tumor microenvironment |
144 | Poster Presentation | RTX-240, an Allogeneic Engineered Red Blood Cell Expressing 4-1BBL and IL-15TP, Promotes NK Cell Functionality In Vitro and In Vivo | Anne-Sophie Dugast; Shannon L. McArdel; Enping Hong; Arjun Bollampalli; Maegan E. Hoover; Sneha Pawar; Viral Amin; Kangjian Qiao; Christopher Ta; Laurence A. Turka; Thomas J. Wickham, PhD; Sivan Elloul; | Cellular Therapies | Costimulation; Cytokine; Immune monitoring; NK/NK T cell |
145 | Poster Presentation | Preclinical Development of EDIT-201, a Multiplexed CRISPR-Cas12a Gene Edited Healthy Donor Derived NK Cells Demonstrating Improved Persistence and Resistance to the Tumor Microenvironment | Karrie K. Wong, Ph.D.; Steven Sexton; Kelly Donahue; Lincy Prem Antony; Kevin Wasko; Jared Nasser, BS; Glenn Leary; Amanda Pfautz; Owen Porth; William Pierce; Patricia Sousa; Sean N. Scott; Aaron C. Wilson; Kai-Hsin Chang, Ph.D.; John A. Zuris, Ph.D.; Christopher J. Wilson, Ph.D.; Richard A. Morgan, Ph.D.; Christopher M. Borges, Ph.D.; | Cellular Therapies | NK/NK T cell; Solid tumors; Tumor microenvironment |
146 | Poster Presentation | Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1 | Alma-Martina Cepika; Pauline P. Chen; Molly J. Uyeda; Brandon Cieniewicz; Mansi Narula; Laura Amaya; David M. Louis; Liwen Xu; Xuhuai Ji; Alice Bertaina; Rajni Agarwal-Hashmi; Mark M. Davis; Everett Meyer; Rosa Bacchetta; Maria Grazia Roncarolo | Cellular Therapies | Adoptive immunotherapy; Immune suppression; Immune tolerance; Leukemia/Lymphoma; Regulatory T cell (Treg cell); T cell |
147 | Poster Presentation | CD155 blockade boosts alloreactive natural killer cell antitumor effects against osteosarcoma | Monica M. Cho, BSE; Monica M. Cho, BSE; Madison F. Phillips; Longzhen Song, Ph.D.; Amy K. Erbe, PhD; Christian M. Capitini, MD; | Cellular Therapies | Adoptive immunotherapy; NK/NKT cell; Pediatric tumors; Solid tumors |
148 | Poster Presentation | Identification of prostate-restricted epithelial antigens for transgenic T cell adoptive therapy against prostate cancer | Diana DeLucia, PhD; Tiffany Pariva; Roland Strong; Owen Witte; John Lee; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Tumor antigens |
149 | Poster Presentation | GEN-011: An ATLASTM-guided peripheral-blood derived neoantigen-specific T cell therapy designed to improve on TIL approaches | Pranay D. Khare, PhD; Harshal Zope; James Perry; Victoria L. DeVault, PhD; Mercay R. Reuter; Adrienne Li, PhD; Daniel B. DeOliveira, PhD; Hubert Lam, PhD; Manish Jain, PhD; Jessica B. Flechtner, PhD; Pranay D. Khare, PhD; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
150 | Poster Presentation | GAIA-102: a new class off-the-shelf allogeneic NK-like cells that can eliminate solid tumors | Yui Harada, PhD; Yoshikazu Yonemitsu, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors |
151 | Poster Presentation | Combination NK-92MICD64 cell therapy approach with therapeutic antibodies to treat metastatic prostate cancer | Hallie Hintz, BA; Bruce Walcheck; Aaron LeBeau; | Cellular Therapies | Antibody; NK/NKT cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
152 | Oral Presentation | Adoptive T cell therapy targeting somatic p53 mutations | Peter Kim, PhD; Parisa Malekzadeh, MD; Nolan Vale; Elizabeth Hedges; Nikolaos Zacharakis, PhD, MS; Steven A. Rosenberg, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs) |
153 | Poster Presentation | NEO-PTC-01 (BNT-221), an autologous neoantigen-specific T-cell product for adoptive cell therapy of metastatic melanoma | Divya R. Lenkala, MS; Jessica Kohler, PhD; Brian McCarthy; Michael Nelson; Jonathan McGee; Daniel Kallin; Janani Sridar; Paul Turcott; Dewi Harjanto; Cynthia Nijenhuis; Joost H. Van Den Berg, PharmD; Richard B. Gaynor, MD; Marit M. Van Buuren, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Dendritic cell; Neoantigens; T cell |
154 | Poster Presentation | Marrow-infiltrating Lymphocytes (MILs): A Novel Adoptive Immunotherapy for Hematological and Solid Tumors | Eric R. Lutz, PhD; Lakshmi Rudraraju, MS; Elizabeth DeOliveira; Amanda L. Seiz; Monil Shah, PharmD; Celine Colmenares; Beverly Dan Fu; Daniela Bota, MD, PhD; Collin Brummel; Chad Brenner, PhD; Paul Swiecicki, MD; Nicole E. Fredrich; David B. Page, MD; Eleni Efstatihiou, MD, PhD; Ivan M. Borrello, MD; Kimberly A. Noonan, PhD, MPH; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell |
155 | Poster Presentation | iPSC-derived NK cells mediate robust anti-tumor activity against glioblastoma | Jeff S. Miller, MD; Frank S. Cichocki, PhD; Jianfang Ning; Ryan Bjordahl, PhD; Zachary B. Davis, PhD; Katie Tuininga; Hongbo Wang; Paul Rogers; Moyar Ge; Tom T. Lee; Bob Valamehr, PhD; Clark C. Chen; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors |
156 | Poster Presentation | Discovery of TSC-100: A Natural HA-1-specific TCR to Treat Leukemia Following Hematopoietic Stem Cell Transplant Therapy | Ribhu Nayar, Ph.D.; Sonal Jangalwe; Mollie M. Jurewicz; Antoine J. Boudot; Andrew S. Basinski; Robert Prenovitz; Elizabeth A. Olesin; Daniel C. Pollacksmith; Qikai Xu; Yifan Wang; Amy Virbasius; Jeffery Li; Holly Whitton; Garrett S. Dunlap; Alexander Cristofaro; Nancy Nabilsi; Ruan Zhang; Candace Perullo; Sida Liao; Kenneth L. Jahan; Kenneth Olivier; Gavin MacBeath, Ph.D.; | Cellular Therapies | Adoptive immunotherapy; Genetic polymorphism; Inflammation; Leukemia/Lymphoma; T cell; Targeted therapy; Tumor antigens |
157 | Poster Presentation | A critical role of CD40 and CD70 signaling in cDC1s in expansion and antitumor efficacy of adoptively transferred tumor-specific T cells | Takaaki Oba, MD,PhD; Toshifumi Hoki, MD,PhD; Takayoshi Yamauchi; Tibor Keler, PhD; Henry C. Marsh; Xuefang Cao; Fumito Ito; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Costimulation; Dendritic cell |
158 | Poster Presentation | Inhibition of PI3Kδ improves tumor specific T cell immunity and metabolic fitness | Guillermo O. Rangel RIvera, B.S.; Guillermo O. Rangel RIvera, B.S.; Connor J. Dwyer, PhD; Dimitrios C. Arhontoulis; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Megan M. Wyatt, MS; Amalia M. Rivera Reyes, BS; Chrystal M. Paulos, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
159 | Poster Presentation | Adoptively transferred CD8+ T cells that target neoantigen persist and regress melanomas to a greater extent than those that target self/tumor-antigen | Amalia M. Rivera Reyes, BS; Megan M. Wyatt, MS; Connor J. Dwyer, PhD; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Guillermo O. Rangel RIvera, B.S.; Chrystal M. Paulos, PhD; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Solid tumors |
160 | Poster Presentation | TLR9-activated B cells imprint adoptively transferred CD8+ T cells with potent tumor immunity and persistence in vivo | Aubrey S. Smith, BS; Hannah M. Knochelmann, BS; Connor J. Dwyer, PhD; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Amalia M. Rivera Reyes, BS; Jessica E. Thaxton, PhD, MS; Eric C. Bartee, PhD; Mark P. Rubinstein, PhD; Bei Liu, MD MPH; Chrystal M. Paulos, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; B cell; Proteomics; T cell; TLR; Tumor infiltrating lymphocytes (TILs) |
161 | Poster Presentation | Development of a CD8 co-receptor independent T cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T cell-based immunotherapy | Kathrin Davari, PHD; Tristan Holland; Laura Prassmayer; Giulia Longinotti; Kenneth Ganley; Lisa J. Pechilis; Iulia Diaconu; Prashant R. Nambiar; Mike S. Magee; Dolores J. Schendel, PhD; Daniel Sommermeyer, PhD; Christian Ellinger, Dr. Rer. Nat.; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Targeted therapy; Tumor antigens |
163 | Poster Presentation | NICE: Neoantigen-Cytokine-Chemokine Multifunctional Engager for NK cell immunotherapy of solid tumors | Xue Yao, MS; Sandro Matosevic, PhD; | Cellular Therapies | Adoptive immunotherapy; Bispecifics; Chemokine; Cytokine; Neoantigens; NK/NK T cell; Solid tumors; Tumor antigens; Tumor microenvironment |
164 | Poster Presentation | AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing | Burcu Yigit, PhD; Xavier Michelet, PhD; Shalu S. Kharkwal; Eleni Chantzoura, PhD; Jan Bergmann; Alvaro Sebastian Yague, Ph.D; Simon Yue; Darrian Moskowitz; Benjamin Wolf, PhD; Mark A. Exley, PhD; Dhan Chand, PhD; Marc A. Van Dijk, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; NK/NK T cell |
165 | Poster Presentation | Activating antigen carriers generated with microfluidics cell squeezing drive effective anti-tumor responses | Katarina Blagovic, PhD; Katarina Blagovic, PhD; Katarina Blagovic, PhD; Amritha K. Ramakrishnan, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Katherine J. Seidl, PhD; Defne Yarar, PhD; | Cellular Therapies | Adoptive immunotherapy; Immune adjuvant; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Vaccine |
166 | Poster Presentation | Mucosal-associated invariant T-cells (MAIT) in pancreatic cancer | Jéssica O. Kamiki, Master's student; Patrícia A. António; Pedro Noronha; Carolina Condeço; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Eric De Sousa; Andreia Maia, PhD student; Mireia Castillo-Martin, MD, PhD; Antonio Beltran; Carlos Carvalho, MD; Joana Lérias, DVM; Markus J. Maeurer, MD, PhD, FRCP(London); | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Microbiome; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
167 | Poster Presentation | B-cell-based vaccination elicit potent immunity against glioblastoma | Catalina Lee-Chang, PhD; Jason Miska, PhD; David Hou; Aida Rashidi, MD; Peng Zhang, PhD; Rachel A. Burga, PhD; Crag M. Horbinski, MD, PhD; Roger Stupp, MD; Maciej S. Lesniak, MD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Costimulation; Solid tumors; Tumor microenvironment; Vaccine |
168 | Poster Presentation | A Novel Prostate-Restricted Tumor-Associated Antigen: A Potential Therapeutic Target | Zoila (Areli) A. Lopez Bujanda, MS; Aleksandar Obradovic; Thomas Nirschl; Timothy O’Donnell; Uri Laserson; Rodney Macedo-Gonzales; Ran Reshef, MD, MSc; Tiezheng Yuan; Mithil Soni; Emmanuel S. Antonarakis, MD; Benjamin Larman; Pawel Muranski; Charles G. Drake, MD, PhD; | Cellular Therapies | Antigen presenting cells; Dendritic cell; Neoantigens; Targeted therapy; Tumor antigens |
169 | Poster Presentation | Microfluidics cell squeezing enables human PBMCs as drivers of antigen-specific CD8 T responses across broad range of antigens for diverse clinical applications | Michael F. Maloney, PhD; Scott M. Loughhead, PhD; Amritha K. Ramakrishnan, PhD; Carolyne Smith, PhD; Anita Venkitaraman; Christian Yee; Miye Jacques, MSc; Defne Yarar, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Kelan A. Hlavaty, PhD; Melissa Myint, PhD; Katherine J. Seidl, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Cytokine; T cell; Targeted therapy; Tumor antigens; Vaccine |
170 | Poster Presentation | Microfluidics Cell Squeezing Enables Potent Cellular Vaccines in Murine Models Through Direct Cytosolic Loading and Direct CD8 T Cell Priming | Emrah I. Ozay, PhD; Matthew G. Booty; Katarina Blagovic, PhD; David Soto; Olivia Pryor; Adam Stockmann; Disha Subramanya; Kelly Volk; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Defne Yarar, PhD; Katherine J. Seidl, PhD; Scott M. Loughhead, PhD; | Cellular Therapies | Antigen presenting cells; Chemotherapy; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
171 | Poster Presentation | Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer | Maho Nagasawa; Remco Bos; Haoxiao Zuo; Kiave Yune Ho Wang Yin, PhD; Marie-José van Lierop; Sebastien Tabruyn, PhD; Erik Manting; Marco de Bruyn; Hans Nijman; Satwinder Kaur SK. Singh, PhD; | Cellular Therapies | Dendritic cell; Solid tumors; T cell; Tumor antigens; Vaccine |
172 | Poster Presentation | Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYL(TM) | Colin J. Thalhofer, PhD; Ryan D. Montler, MBA; Melissa Maxwell, MS; Dingxue Yan, PhD; James Cardia, PhD; Simon P. Fricker, PhD; Jacob Moses, B.S.; Joshua Rios, B.S.; Tarsem L. Moudgil, MS; Bernard A. Fox, PhD; Nick P. Morris, PhD; B R. Bell, M.D., DDS; Andrew D. Weinberg, PhD; | Cellular Therapies | Biomarkers; Immune contexture; Immune tolerance; Solid tumors; T cell; T cell lineages; Tumor antigens; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
173 | Poster Presentation | An In Vivo CRISPR/Cas9 Screening Platform to Identify T Cell Enhancing Edits in Distinct Solid Tumor Microenvironments | Amy Becker, PhD; Troy Luster; Ishina Balwani; Nachiket Shevale; Jingwei Sun, PhD; Erica Del Aguila; Jeff Jones; Srijani Sridhar; Nishit Patel; Daniel O'Connell; Reynald Lescarbeau; Birgit C. Schultes; | Cellular Therapies | Adoptive immunotherapy; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
174 | Poster Presentation | An ex vivo tumoroid model of fresh patient tumors (3D-ACT) to assess efficacy of cellular therapy in immuno-oncology | Stephen Iwanowycz, PhD; Jared C. Ehrhart, PhD; Mibel Pabon, PhD; Tina Pastoor; Jenny Kreahling, PhD; Soner Altiok, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; CAR T cells; Cytokine; Gene expression; Immune monitoring; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
175 | Poster Presentation | A Fas-4-1BB immunomodulatory fusion protein converts a pro-death to a pro-survival signal, enhancing T cell function and efficacy of adoptive cell therapy in murine models of AML and pancreatic cancer | Shannon K. Oda, PhD; Shannon K. Oda, PhD; Kristin G. Anderson, PhD; Philip D. Greenberg, MD; Nicolas Garcia, BS; Pranali Ravikumar; Patrick Bonson; Cody Jenkins; Summer Zhuang; Andrew W. Daman; Shannon K. Oda, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Costimulation; Immune suppression; Leukemia/Lymphoma; Metabolism; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
176 | Poster Presentation | Evaluating the safety of Tumor Treating Fields (TTFields) application to the torso – in vivo studies | Shiri Davidi; Roni Blat; Mijal Munster; Anna Shteingauz; Shay Cahal; Moshe Giladi; Uri Weinberg, MD PhD; Yoram Palti; Moshe Giladi, PhD; | Cellular Therapies | Solid tumors |
177 | Poster Presentation | A severe cytokine release syndrome with respiratory failure in recurrent mesothelioma induced by EpCAM CAR-T cells infusion: a case report | Sitong Wang, PG; Sitong Wang, PG; Juemin Fang; Hui Wang; Qing Xu; | Cellular Therapies | CAR T cells |
764 | Poster Presentation | Expansion with IL-15 increases cytotoxicity of Vγ9Vδ2 T cells and is associated with higher levels of cytotoxic molecules and T-bet | Pia Aehnlich, M.Sc.; Per Thor Straten, PhD; Ana Micaela M. Carnaz Simoes, MSc; Signe K. Skadborg, MSc; Gitte H. Olofsson, BA, MSc; | Cellular Therapies | Adoptive immunotherapy; Cytokine; T cell |
765 | Poster Presentation | Contextual secretion of nanoscale interleukin (IL)-12 by CAR T cells for the treatment of cancer | Zhifen Yang, Dr.; Maggie Bobbins, Dr.; Hana Choi; Ofir Stefanson; Jin Yang, Dr.; Khristina Magallanes; Bing C. Wang, PhD; Lei Stanley Qi, Dr.; Francesco M. Marincola, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Costimulation; Immune contexture; Immune suppression; Monocyte/Macrophage; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
766 | Poster Presentation | Novel bioluminescent bioassays for the discovery and development of T cell redirecting Cancer Therapies | Vanessa Ott, PhD; Julia Gilden, Ph.D.; Jamison J. Grailer, PhD; Michael Slater; Pete Stecha, BS; Jim Hartnett, BS; Dan Lazar; Frank Fan, PhD; Mei Cong, PhD; Zhijie Jey Cheng; | Cellular Therapies | Bispecifics; Adoptive immunotherapy; Antibody; CAR T cells; NK/NK T cell; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
767 | Poster Presentation | Interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies | Stefanie R. Bailey; Sonika Vatsa; Amanda Bouffard; Rebecca Larson; Irene Scarfo; Michael Kann; Andrea Schmidts; Marcela V. Maus, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; B cell; CAR T cells; Chemokine; Cytokine; Immune toxicity; Inflammation; Leukemia/Lymphoma; Monocyte/Macrophage; T cell |
768 | Poster Presentation | Re-directed T cell therapy to control invasive aspergillosis | Karishma Bavisi, PhD; Sebastian Wurster; Nathaniel Albert; Sattva S. Neelapu, MD; Dimitrios P. Kontoyiannis, MD; Pappanaicke Kumaresan; Kumaresan Pappanaicken; | Cellular Therapies | CAR T cells; Leukemia/Lymphoma |
769 | Poster Presentation | CAR T cells undergoing epigenetic reprogramming by low-dose decitabine enhances persistent anti-tumor efficacy in vivo. | Yao Wang, Ph.D; Weidong Han; Chuan Tong; Zhiqianag Wu; Hanren Dai; | Cellular Therapies | Epigenetics; CAR T cells; Leukemia/Lymphoma; T cell |
770 | Poster Presentation | Analysis of gut microbiome in patients receiving adoptive T-cell therapy (ACT) across different solid tumour types | Arantzazu Barquin Garcia, MD; Sergio Ruiz; Paloma Navarro; Juan Francisco Rodriguez-Moreno; Elena Sevillano, MD; Monica Yague; Sandra Amarilla; Jesus Garcia-Donas; | Cellular Therapies | Adoptive immunotherapy; Microbiome; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
771 | Poster Presentation | Characterization of tumor infiltrating immune cells from adult soft tissue sarcomas | Jacky H. Chen, HBSc; Jay S. Wunder, MD, MSc, FRCSC; Nalan Gokgoz, PhD; Irene L. Andrulis, PhD; | Cellular Therapies | Adoptive immunotherapy; Coinhibition; Costimulation; Cytokine; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
772 | Poster Presentation | A potent and off-the-shelf oNK cell therapy product targets HER2+ cancer cells and resists suppressive tumor microenvironment | Hao-Kang Li, Ph.D; Ching-Wen Hsiao; Sen-Han Yang; Hsiu-Ping Yang; Tai-Sheng Wu; Zih-Fei Cheng; Chia-Yun Lee; Yan-Liang Lin; Yan-Da Lai; Sai-Wen Tang; Janet Pan; Wei-Lun Lo; Shih-Chia Hsiao; | Cellular Therapies | Adoptive immunotherapy; Antibody; NK/NK T cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
773 | Oral Presentation | Adoptive Cell Therapy Response in Melanoma is Mediated by Stem-like CD8 T cells | Sri Krishna, PhD; Frank J. Lowery; Amy R. Copeland; Stephanie L. Goff, MD, FACS; Grégoire Altan-Bonnet; Paul F. Robbins, PhD; Steven A. Rosenberg, MD, PhD; | Cellular Therapies | Biomarkers; Checkpoint blockade; Neoantigens; Solid tumors; Systems biology; T cell |